InvestSMART

Arovella Therapeutics Limited (ASX:ALA)

ALERT: Price-sensitive ASX Announcement for ALA
Current share price for ALA : $0.065 -0.028 (-30.11%)+
Announcement
Release
30 Oct 2025 9:15AM
Price at Release
$0.093
Full Release
download
Summary
Arovella Therapeutics Limited announced its quarterly activities and cash flow report, reflecting a strong financial position with $21.9 million in cash and cash equivalents as of the end of September 2025. Operating cash outflows totaled $2.7 million, primarily due to research and development and staff costs. The company plans to advance its lead program, ALA-101, into a first-in-human clinical trial by early 2026. They also received a $3.2 million R&D Tax Incentive refund. The report includes progress updates on various programs and outlines the company's financial transactions and strategic outlook.
Key Points
  • Operating cash outflows were $2.7 million, focused on R&D and staff costs.
  • $21.9 million in cash and cash equivalents as of 30 September 2025.
  • Preparation for the ALA-101 clinical trial commencing in early 2026.
  • Received $3.2 million R&D Tax Incentive refund.
  • Continued progress on solid tumour program targeting CLDN18.2.
  • Consideration of new technologies to enhance the CAR-iNKT cell platform.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.